PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
October 1, 2023Journal of the American College of Cardiology199 citationsOpen Access

Tricuspid Valve Academic Research Consortium Definitions for Tricuspid Regurgitation and Trial Endpoints

RHRebecca T. HahnMLMatthew LawlorCDCharles J. Davidson

Key Points

Key points are not available for this paper at this time.

Abstract

Interest in the pathophysiology, etiology, management, and outcomes of patients with tricuspid regurgitation (TR) has grown in the wake of multiple natural history studies showing progressively worse outcomes associated with increasing TR severity, even after adjusting for multiple comorbidities. Historically, isolated tricuspid valve surgery has been associated with high in-hospital mortality rates, leading to the development of transcatheter treatment options. The aim of this first Tricuspid Valve Academic Research Consortium document is to standardize definitions of disease etiology and severity, as well as endpoints for trials that aim to address the gaps in our knowledge related to identification and management of patients with TR. Standardizing endpoints for trials should provide consistency and enable meaningful comparisons between clinical trials. A second Tricuspid Valve Academic Research Consortium document will focus on further defining trial endpoints and will discuss trial design options.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Hahn et al. (2023) studied this question. Increasing severity of tricuspid regurgitation is associated with progressively worse outcomes, even after adjusting for comorbidities.

synapsesocial.com/papers/6962d053f86a112dd98ba673https://doi.org/10.1016/j.jacc.2023.08.008
Ask AI
Helpful
Bookmark
Share
View Full Paper